These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 20625290)

  • 21. Mineralocorticoid receptor activation and blockade: an emerging paradigm in chronic kidney disease.
    Bertocchio JP; Warnock DG; Jaisser F
    Kidney Int; 2011 May; 79(10):1051-60. PubMed ID: 21412221
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Successful effect of triple blockade of renin-angiotensin-aldosterone system on massive proteinuria in a patient with chronic kidney disease.
    Kuriyama S; Sugano N; Ueda H; Otsuka Y; Kanzaki G; Hosoya T
    Clin Exp Nephrol; 2009 Dec; 13(6):663-6. PubMed ID: 19629623
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Does blockade of the Renin-Angiotensin-aldosterone system slow progression of all forms of kidney disease?
    Lattanzio MR; Weir MR
    Curr Hypertens Rep; 2010 Oct; 12(5):369-77. PubMed ID: 20703958
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The cardiovascular effects of eplerenone, a selective aldosterone-receptor antagonist.
    Davis KL; Nappi JM
    Clin Ther; 2003 Nov; 25(11):2647-68. PubMed ID: 14693297
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mineralocorticoid Antagonism and Diabetic Kidney Disease.
    Lytvyn Y; Godoy LC; Scholtes RA; van Raalte DH; Cherney DZ
    Curr Diab Rep; 2019 Jan; 19(1):4. PubMed ID: 30673886
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacotherapy: Cardiovascular effects of aldosterone blockade in CKD.
    Pitt B
    Nat Rev Cardiol; 2009 Nov; 6(11):679-80. PubMed ID: 19851348
    [No Abstract]   [Full Text] [Related]  

  • 27. Predictors of hyperkalemia risk following hypertension control with aldosterone blockade.
    Khosla N; Kalaitzidis R; Bakris GL
    Am J Nephrol; 2009; 30(5):418-24. PubMed ID: 19738369
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rationale and design of the Eplerenone combination Versus conventional Agents to Lower blood pressure on Urinary Antialbuminuric Treatment Effect (EVALUATE) trial: a double-blinded randomized placebo-controlled trial to evaluate the antialbuminuric effects of an aldosterone blocker in hypertensive patients with albuminuria.
    Ando K; Ohtsu H; Arakawa Y; Kubota K; Yamaguchi T; Nagase M; Yamada A; Fujita T;
    Hypertens Res; 2010 Jun; 33(6):616-21. PubMed ID: 20379190
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Eplerenone: selective aldosterone antagonism in management of cardiovascular and renal disease.
    Brennan BJ; Martin NE
    J Am Pharm Assoc (2003); 2004; 44(5):604-10; quiz 610-1. PubMed ID: 15496047
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mechanisms of impaired potassium handling with dual renin-angiotensin-aldosterone blockade in chronic kidney disease.
    Preston RA; Afshartous D; Garg D; Medrano S; Alonso AB; Rodriguez R
    Hypertension; 2009 May; 53(5):754-60. PubMed ID: 19307466
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nonsteroidal mineralocorticoid antagonists in diabetic kidney disease.
    Dojki FK; Bakris G
    Curr Opin Nephrol Hypertens; 2017 Sep; 26(5):368-374. PubMed ID: 28771453
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Mineralocorticoid receptor antagonists in chronic kidney disease - pros and cons].
    Jędras M; Filipowicz E
    Wiad Lek; 2017; 70(6 pt 2):1205-1208. PubMed ID: 29533915
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mineralocorticoid Receptor Antagonists for Nephroprotection: Current Evidence and Future Perspectives.
    Sarafidis PA; Memmos E; Alexandrou ME; Papagianni A
    Curr Pharm Des; 2018; 24(46):5528-5536. PubMed ID: 30848187
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Renoprotective effects of mineralocorticoid receptor blockers in patients with proteinuric kidney diseases.
    Morales E; Millet VG; Rojas-Rivera J; Huerta A; Gutiérrez E; Gutiérrez-Solís E; Egido J; Praga M
    Nephrol Dial Transplant; 2013 Feb; 28(2):405-12. PubMed ID: 23222416
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hyperkalemia risk in chronic kidney disease: deterrent to the use of aldosterone receptor antagonism or not.
    Sica DA
    Hypertension; 2009 May; 53(5):749-50. PubMed ID: 19307465
    [No Abstract]   [Full Text] [Related]  

  • 36. Mineralocorticoid receptor activation and mineralocorticoid receptor antagonist treatment in cardiac and renal diseases.
    Bauersachs J; Jaisser F; Toto R
    Hypertension; 2015 Feb; 65(2):257-63. PubMed ID: 25368026
    [No Abstract]   [Full Text] [Related]  

  • 37. Prediction and management of hyperkalemia across the spectrum of chronic kidney disease.
    Lazich I; Bakris GL
    Semin Nephrol; 2014 May; 34(3):333-9. PubMed ID: 25016403
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Antifibrotic renal role of mineralcorticoid receptor antagonists].
    Ocello A; La Rosa S; Fiorini F; Randone S; Maccarrone R; Battaglia G; Granata A
    G Ital Nefrol; 2019 Jul; 36(4):. PubMed ID: 31373464
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predictors of hyperkalemia risk after hypertension control with aldosterone blockade according to the presence or absence of chronic kidney disease.
    Gwoo S; Kim YN; Shin HS; Jung YS; Rim H
    Nephron Clin Pract; 2014; 128(3-4):381-6. PubMed ID: 25572273
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of spironolactone in combination with angiotensin-converting enzyme inhibitors or Angiotensin receptor blockers in patients with proteinuria.
    Kim HY; Bae EH; Ma SK; Kim SW
    Kidney Blood Press Res; 2014; 39(6):573-80. PubMed ID: 25531940
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.